Ardelyx, Inc. (ARDX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Ardelyx, Inc. (ARDX) closed at USD 3.27 on 2026-10-15, a change of -34.1 % over the past year, with a market capitalization of USD 797.8M.

Ardelyx, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Ardelyx, Inc. key figures

Previous close

USD 3.27 (2026-10-15)

1-year change

-34.1 %

Market cap

USD 797.8M

Enterprise value

USD 770.67M

P/E ratio (trailing)

-13.44

P/E ratio (forward)

10.64

EPS (trailing)

-0.23

EPS (forward)

0.29

PEG ratio

n/a

Price to book

5.17

Revenue growth

23.8 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

6.68

Employees

489

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Ardelyx, Inc.

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Ardelyx, Inc. and compare it with other stocks.